Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: A preliminary study on the role of P2Y12 receptor monitoring

European Journal of Anaesthesiology

Volumn 27, Issue 2, 2010, Pages 138-145

  Metzlera, Helfried ^a   Prüllerb, Florian ^a   Müncha, Andreas ^a   Primusc, Günter ^a   Kainza, Johann ^a   Hödld, Ronald ^a   Rehake, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Antiplatelet drugs; Clopidogrel; Coronary stents; Noncardiac surgery; Platelet function

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE; PHOSPHOPROTEIN; PURINERGIC P2Y12 RECEPTOR; VASODILATOR AGENT; ACTIN BINDING PROTEIN; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; DRUG DERIVATIVE; PURINERGIC P2 RECEPTOR; TICLOPIDINE; VASODILATOR STIMULATED PHOSPHOPROTEIN; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ARTICLE; ASSAY; CARDIAC PATIENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONITORING; PLATELET REACTIVITY INDEX; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; STROKE; SURGICAL PATIENT; THROMBOCYTE FUNCTION; BLEEDING; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; METABOLISM; METHODOLOGY; MIDDLE AGED; PHOSPHORYLATION; PREOPERATIVE CARE; TIME;

ADULT; AGED; ASPIRIN; BLOOD LOSS, SURGICAL; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; FEMALE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2; TICLOPIDINE; TIME FACTORS;

EID: 77950351431     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e32832eb521     Document Type: Article

References (39)

1. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in unstable angina to prevent recurrent events trial investigators: Effects of clopidogrel in addition to aspirin with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
2. Mehta SR, Yusuf S, Peters RJ. Clopidogrel in unstable angina to prevent recurrent events trial (CURE) investigators: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358:527-533.
3. Steinhubl SR, Berger PB, Mann JT III. Clopidogrel for the reduction of events during observation (CREDO) investigators: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288:2411-2420.
4. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115:813-818.
5. Slottow TLP, Waksman R. Overview of the 2006 food and drug administration circulatory system devices panel meeting on drug-eluting stent thrombosis. Cath Cardiovasc Interv 2007; 69:1064-1074. (Pubitemid 46900788)
6. Bassand J, and the Task Force Members. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force of the European Society of Cardiology. Eur Heart J 2007; 28:1598-1660.
7. Ho PM, Petersen ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299:532-539.
8. Spertus JA, Kettelkamp R, Vance C, et al. Prevalance, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006; 113:2803-2809.
9. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on cardiovascular radiology and intervention: The American Academy of Neurology affirms the value to this guideline. Circulation 2006; 113:e409-e449. (Pubitemid 43739468)
10. Bates ER, Babb JD, Casey DE, et al. ACCF/SCAI/SVMB/SIR/ASTIN 2007 clinical expert consensus document of carotid stenting. J Am Coll Cardiol 2007; 49:126-170.
11. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000; 35:1288-1294.
12. Vicenzi MN, Ribitsch D, Luha O, et al. Coronary artery stenting before noncardiac surgery: More threat than safety? Anesthesiology 2001; 94:367-368.
13. Llau JV, López-Forte C, Sapena L, Ferrandis R. Perioperative management of antiplatelet agents in noncardiac surgery. Eur J Anaesth 2009; 26:181-187.
14. Metzler H, Huber K, Kozek-Langenecker S. Anaesthesia in patients with drug-eluting stents. Curr Opin Anaesthesiol 2008; 21:55-59.
15. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2007; 116:e418-e499.
16. Chassot PG, Delabays A, Spahn DR. Perioperative antiplatelet therapy: The case for continuing therapy in patients at risk of myocardial infarction. Br J Anaesth 2007; 99:316-328.
17. Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol 2007; 49:2145-2150.
18. Albaladejo P, Marret E, Piriou V, Samama CM. Perioperative management of antiplatelet agents in patients with coronary stents: Recommendations of a French Task Force. Br J Anaesth 2006; 97:580-585.
19. Gurbel PA, Lau WC, Tantry US. Omeprazole. A possible new candidate influencing the antiplatelet effect of clopidogrel [editorial comment]. J Am Coll Cardiol 2008; 51:261-263.
20. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. J Am Coll Cardiol 2005; 46:1827-1832.
21. Pampuch A, Cerletti C, de Gaetano G. Comparison of VASPphosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. J Thromb Haemost 2006; 96:767-773.
22. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98:838-843.
23. Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilatorstimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98:1329-1334.
24. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phophorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3:85-92.
25. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. J Am Coll Cardiol 2008; 51:1404-1411.
26. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50:1822-1834.
27. Michelson AD, Frelinger AL, Furman MI. Current opinions in platelet function testing. Am J Cardiol 2006; 98:4N-10N.
28. Kleiman NS. Will measuring vasodilator-stimulated phosphoprotein phosphorylation help us optimize the loading dose of clopidogrel [editorial comment]? J Am Coll Cardiol 2008; 51:1412-1414.
29. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilatorstimulated phophoprotein phophorylation. Cathet Cardiovasc Interv 2003; 59:295-302.
30. Cuisset T, Frere C, Quilici J, et al. High posttreatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 5:542-549.
31. Weber AA, Braun M, Hohlfeld T, et al. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 2001; 52:333-336.
32. Eagle KA and the Task Force on Practice Guidelines: ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery: Summary article: A report of the American College of Cardiology/American Heart Association. Circulation 2004; 110:1168-1176.
33. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908-2913.
34. Gurbel PA, Tantry US. Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 2006; 3:387-395.
35. Storey RF. Variability of response to antiplatelet therapy. Eur Heart J 2008; 10:A21-A27.
36. LauWC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2005; 109:166-171.
37. Gilard M, Arnaud B, Cornily J-C. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omaprezole Clodpidogrel Aspirin) study. J Am Coll Cardiol 2008; 51:256-260.
38. Gurbel PA, Lau WC, Tantry US. Omeprazole. A possible new candidate influencing the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 51:261-263.
39. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55:780-784.